Raw Material Overview

Chrysanthemum & Ecklonia Cava Extract Complex
Chrysanthemum & Ecklonia Cava Extract Complex
The Chrysanthemum & Ecklonia Cava Extract Complex, an individually recognized ingredient for respiratory health, is a 100% plant-based material formulated by combining separate extracts of active components from Chrysanthemum indicum (Kamguk) and Ecklonia cava (Gamtae), both effective for respiratory health.
  • Approved as an MFDS Individually Recognized Ingredient (No. 2025-33)

    - Greenstore Ingredient Distribution

  • May help improve bronchial conditions (e.g., cough, phlegm)
  • Human clinical trials confirmed improvements in allergic bronchial inflammation, chronic inflammatory status, and pathological indicators
Material Name Chrysanthemum & Ecklonia Cava Extract Complex
Materials Chrysanthemum indicum (Part Used: Flower), 
Ecklonia cava (Part Used: Whole)
Dosage 700 mg/day (as Kamguk-Gamtae Extract
Functionality May help improve bronchial conditions Marker
Components ① Luteolin-7-glucoside    ② Dieckol
Human Clinical Trial Duration 12 weeks
Human Clinical Trial
  • Test Material

    Chrysanthemum & Ecklonia Cava Extract Complex

  • Study Design

    Multi-center, randomized, double-blind, placebo-controlled

  • Intake Period & Dosage

    12 weeks

Improvement in Respiratory Symptoms Confirmed via BCSS
BCSS Questionnaire

(Breathless, Cough, and Sputum Scale)

  • A survey tool used to evaluate the primary respiratory symptoms of breathlessness, cough, and sputum.
  • An objective indicator used to assess symptoms of acute exacerbation in chronic bronchitis.
  • Consists of 4 items scored from 0 to 4, where a higher score indicates more severe symptoms.
  • A larger decrease in the score is interpreted as a greater symptom relief effect.
Total Score
Breathing
Sputum
  • Test group
  • Control group
In the analysis of total score change, the test group showed a decrease of 3.38±2.28 points,
while the control group showed a decrease of 2.02±3.27 points, revealing a statistically significant difference between the groups.

In the analysis of the Breathing score change, the test group showed a decrease of 0.94±1.16 points,
and the control group showed a decrease of 0.46±1.11 points, with a statistically significant difference between the groups.

In the analysis of the Sputum score change, the test group showed a decrease of 1.02±1.01 points,
compared to the control group's decrease of 0.79±1.26 points, showing a statistically significant difference between the groups.
Improvement Confirmed in VAS Respiratory Symptoms and FEV1
VAS Questionnaire

(Visual Analogue Scale)

  • A subjective assessment tool for cough, sputum, and dyspnea (or chest tightness).
  • A method where the subject marks their perceived level of discomfort on a 0–100mm line.
  • A higher score indicates more severe symptoms, and a larger decrease in the score is interpreted as a greater symptom relief effect.
FEV1

(Forced Expired Volume in one second /
Pulmonary Function Test)

  • A representative pulmonary function test (PFT) indicator for quantitatively assessing respiratory function.
  • A method measuring the volume of air exhaled in the first second after a maximal inhalation.
  • A larger increase in the score is interpreted as a greater symptom relief effect.
Cough
Phlegm
FEV1
  • Test group
  • Control group
*Analysis of the change in Cough VAS (Visual Analog Scale) showed a reduction of 28.79±27.78 mm in the treatment group,
compared to a 13.07±29.67 mm reduction in the control group, confirming a statistically significant difference between the groups.

*Analysis of the change in Phlegm VAS showed a reduction of 34.83±28.99 mm in the treatment group,
compared to a 16.60±34.61 mm reduction in the control group, confirming a statistically significant difference between the groups.

*In the pulmonary function test, analysis of the change in FEV1 (Forced Expiratory Volume in 1 second) showed a reduction of 0.01±0.36 L in the treatment group,
compared to a 0.17±0.38 L reduction in the control group, confirming a statistically significant difference between the groups.
Functional Effects
Biomarkers for Assessing Improvement in Airway and Bronchial Health
(According to the MFDS Guideline for Evaluating Respiratory Health Functionality)
Category Chrysanthemum &
Ecklonia Cava Extract Complex
Inflammatory Markers Improvement of Allergic Inflammation in Bronchi ○
 Improvement of Chronic Inflammatory State ○
Improvement of Antioxidant Capacity in Bronchi (NO) ○
Pathological Indicators  Improvement of Muscle Contraction Level ○
 Improvement of Mucus Hypersecretion ○
Clinical Indicators BCSS Questionnaire Assessmen Total Score ○
Phlegm ○
Dyspnea ○
 VAS Questionnaire Assessment Cough ○
Phlegm ○
 Respiratory Function Test s
(Forced Expiratory Volume in 1 second (FEV1))
○
Improvement of Allergic Inflammation in Bronchi
Improvement of Chronic Inflammatory State
Improvement of Pathological Indicators
Animal Study Results
  • Test Substance

    Chrysanthemum & Ecklonia Cava Extract Complex

  • Study Design

    PMA-induced lung epithelial cell (A549) model

ED : Chrysanthemum & Ecklonia Cava Extract Complex
Inhibitory Effect on Mucus
Hypersecretion Inhibition of MAPK Signaling Pathway
*Treatment with the Chrysanthemum & Ecklonia Cava Extract Complex (ED) showed dose-dependent inhibition of MUC5AC expression,
with a particularly potent inhibitory effect observed at 40µg/mL.

*The Chrysanthemum & Ecklonia Cava Extract Complex (ED) significantly inhibited the PMA-activated phosphorylation of p-ERK, p-JNK, and p-p38.

*It was demonstrated that the Chrysanthemum & Ecklonia Cava Extract Complex inhibits the expression of MUC5AC,
the major gene for mucus production, by blocking the activation of the MAPK pathway induced by PMA.
  • Test Substance

    Chrysanthemum & Ecklonia Cava Extract Complex

  • Study Design

    Treatment Group: Oral administration of ED (Chrysanthemum & Ecklonia Cava Extract Complex, 300mg/kg)
    Positive Control Group: Oral administration of Bronpass* (300mg/kg)
    Negative Control Group: Oral administration of DW (Distilled Water)
    *Bronpass = A pharmaceutical drug for acute bronchitis

Improvement Effect on Bronchial Inflammation
*Analysis of the bronchoalveolar lavage fluid (BALF) showed a large infiltration of inflammatory cells in the group treated with OVA (ovalbumin) alone.
However, the number of inflammatory cells was reduced in the group administered with the Chrysanthemum & Ecklonia Cava Extract Complex (ED).

*Quantitative analysis revealed that the administration of the Chrysanthemum & Ecklonia Cava Extract Complex (ED)
after OVA induction decreased the number of inflammatory cells, demonstrating an effect similar to that of the positive control group.
Anti-inflammatory and Anti-mucus Effects
*In the H&E staining results, the OVA-treated group exhibited thickened alveolar walls and a large infiltration of inflammatory cells.
In contrast, the group administered with the Chrysanthemum & Ecklonia Cava Extract Complex (ED) showed preserved tissue structure and a reduced pattern of inflammatory cell infiltration.

*The PAS staining results confirmed that the OVA-treated group was stained dark purple due to mucus accumulation.
In contrast, the group administered with the Chrysanthemum & Ecklonia Cava Extract Complex (ED) showed a distinct pattern of suppressed mucus secretion.
Inhibitory Effect on Inflammatory Cytokines
Lung Tissue Analysis
COX-2
iNOS
TNF-α
IL-1β
Serum Analysis
IL-6
  • Analysis of inflammation-related gene expression in lung tissue confirmed that the expression of COX-2, iNOS, TNF-α, and IL-1β was significantly increased in the OVA-treated group. Administration of the Chrysanthemum & Ecklonia Cava Extract Complex (ED) was confirmed to significantly suppress this inflammatory gene expression.
  • Measurement of serum IL-6 levels by ELISA confirmed that the IL-6 level was significantly lower in the group administered with the Chrysanthemum & Ecklonia Cava Extract Complex (ED).
  • Overall, the effects were similar to those of the positive control group, and for some factors, the effects were even superior.
Amelioration of Pulmonary Inflammation
  • Test Substance

    Chrysanthemum & Ecklonia Cava Extract Complex

  • Study Design

    *Particulate Matter (PM2.5)-induced lung inflammation BALB/c mouse model
    Treatment Group: Oral administration of ED (Chrysanthemum & Ecklonia Cava Extract Complex, 300mg/kg)
    *Positive Control Group: Oral administration of Bronpass* (300mg/kg)
    *Negative Control Group: Oral administration of DW (Distilled Water)
    *Bronpass = A pharmaceutical drug for acute bronchitis

Improvement in Inflammatory Cell Count in Bronchoalveolar Lavage Fluid (BALF)
Improvement Effect on Tissue Inflammation via H&E and PAS Staining
*Analysis of the total inflammatory cell count in the BALF showed that the number of inflammatory cells was markedly increased in the PM2.5-treated group.
In the group administered with the Chrysanthemum & Ecklonia Cava Extract Complex (ED),
the inflammatory cell count was not only significantly decreased but also showed an effect superior to that of the positive control group.

*Histological analysis revealed that the PM2.5-treated group exhibited lung tissue damage, inflammatory cell infiltration, and mucus hypersecretion.
In contrast, the group administered with the Chrysanthemum & Ecklonia Cava Extract Complex (ED) showed preserved tissue structure,
and inflammatory responses and mucus production were markedly suppressed.
Inhibitory Effect on Serum Inflammatory Cytokines
 Inhibitory Effect on Inflammatory Gene Expression in Lung Tissue
*Analysis of serum inflammatory cytokine levels showed that TNF-α and IL-6 levels were increased by PM2.5.
Upon administration of the Chrysanthemum & Ecklonia Cava Extract Complex (ED), both indicators were significantly decreased.

*Analysis of inflammatory gene expression in lung tissue showed that the expression of TNF-α, IL-1β, and IL-6 was greatly increased in the PM2.5-treated group.
However, in the group administered with the Chrysanthemum & Ecklonia Cava Extract Complex (ED), all these indicators were confirmed to be significantly suppressed.
Mechanism of Action
Patent
  • Korea Registration
  • Korea Registration
  • Korea Application